RFP | January 22, 2015
U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI) announces the availability of funding for implementation of the Assay Validation for High Quality Markers for NCI-Supported Clinical Trials (UH2/UH3) Grant. The purpose of this grant is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. Contractors should refer to Section VII, Agency Contacts, in the RFP for information regarding each Institute's grants management contact for this program . . .